X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AMAR REMEDIES Fact Sheet, AMAR REMEDIES Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES Fact Sheet   (AMAD)

Here is the latest financial fact sheet of AMAR REMEDIES. For more details, see the AMAR REMEDIES quarterly results and AMAR REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

AMAR REMEDIES Price History

Price Rs 6.1
Mkt Cap Rs m 159
Vol '000 139.7
P/E X -0.5
P/CF X 0.3
EPS (TTM) Rs -12.0
% ch % 0.5
No. of shares m 26.16
% ch week % -7.6
% ch 1-mth % -18.5
% ch 12-mth % -82.7
52 week H/L Rs 48.0/5.5
(As on Dec 11, 2013 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AMAR REMEDIES Financials

No. of Mths
Year Ending
12
Jun-08
12
Jun-09
*
12
Jun-10
*
12
Jun-11
*
12
Jun-12
*
5-Yr Chart
Click to enlarge
AMAR REMEDIES EQUITY SHARE DATA
High Rs583979171164 
Low Rs2113247586 
Sales per share (Unadj.) Rs114.0141.1187.6228.2261.6 
Earnings per share (Unadj.) Rs8.310.212.614.917.4 
Diluted earnings per shareRs8.310.212.614.917.4 
Cash flow per share (Unadj.) Rs9.212.916.619.222.3 
Dividends per share (Unadj.) Rs01.001.001.000 
Adj. dividends per shareRs0.001.001.001.000.00 
Dividend yield (eoy) %03.81.90.80 
Book value per share (Unadj.) Rs47.656.868.383.2100.7 
Adj. book value per shareRs47.656.868.383.2100.7 
Shares outstanding (eoy) m26.1626.1626.1626.1626.16 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.30.20.30.50.5 
Avg P/E ratio x4.72.64.18.27.2 
P/CF ratio (eoy) x4.32.03.16.45.6 
Price / Book Value ratio x0.80.50.81.51.2 
Dividend payout %09.88.06.70 
Avg Mkt Cap Rs m1,0336801,3473,2183,270 
No. of employees `000NANANANANA 
Total wages/salary Rs m8380108128163 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
AMAR REMEDIES INCOME DATA
Net Sales Rs m2,9823,6924,9085,9706,844 
Other income Rs m319111021 
Total revenues Rs m2,9853,7114,9195,9806,865 
Gross profit Rs m3564756868331,131 
Depreciation Rs m2272104110128 
Interest Rs m76124208274398 
Profit before tax Rs m261298385459626 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000-50 
Tax Rs m43325668121 
Profit after tax Rs m218266329391455 
Gross profit margin %11.912.914.014.016.5 
Effective tax rate %16.510.714.514.819.3 
Net profit margin %7.37.26.76.56.6 
AMAR REMEDIES BALANCE SHEET DATA
Current assets Rs m1,2551,7622,4713,3344,904 
Current liabilities Rs m2834766012,4703,581 
Net working cap to sales %32.634.838.114.519.3 
Current ratio x4.43.74.11.31.4 
Inventory Days Days60798593124 
Debtors Days Days83818387100 
Net fixed assets Rs m8401,0821,1621,3821,689 
Share capital Rs m262262262262262 
"Free" reserves Rs m1,0081,2441,5421,9032,358 
Net worth Rs m1,2451,4851,7882,1772,635 
Long term debt Rs m423730275507 
Total assets Rs m2,0952,8463,6334,9286,862 
Interest coverage x4.43.42.92.72.6 
Debt to equity ratio x0000.10.2 
Sales to assets ratio x1.41.31.41.21.0 
Return on assets %14.013.714.813.512.4 
Return on equity %17.517.918.418.017.3 
Return on capital %26.227.732.629.931.0 
Exports to sales %1.33.51.71.34.0 
Imports to sales %00000 
Exports (fob) Rs m381298180273 
Imports (cif) Rs m00000 
Fx inflow Rs m381298180273 
Fx outflow Rs m715412 
Net fx Rs m311147779271 
AMAR REMEDIES CASH FLOW
From Operations Rs m 20 25 -110 -18 -313 
From Investments Rs m -48 -314 -186 -471 -489 
From Financial Activity Rs m 29 295 328 571 769 
Net Cashflow Rs m 0 6 31 82 -33 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 25.5%
Foreign collaborators 0.0%
Indian inst/Mut Fund 9.2%
FIIs 0.0%
ADR/GDR 0.0%
Free float 65.3%
Shareholders 13,061
Pledged promoter(s) holding 99.7%
 

Company Information

REGD OFF B-G01, Marathon Innova, Ganpatrao Kadam Marg, Lower Parel, Mumbai-13
E-MAIL investors@amarremedies.com WEB www.amarremedies.com
TELEPHONE (022) 6556 8091 FAX NA
SECTOR CONSUMER PRODUCTS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Shyam C. Agrawal & Co.
CHM: Pravin N. Shah COMP SEC: Jagdish Nagpal YEAR OF INC: 1984 BSE CODE: 532664 FV (Rs): 10 DIV YIELD (%): -

More Consumer Products Company Fact Sheets:   ASTRAZENECA PHARMA  AJANTA PHARMA  STRIDES SHASUN LTD  DISHMAN PHARMA  ALEMBIC LTD  

Compare AMAR REMEDIES With:   ASTRAZENECA PHARMA  AJANTA PHARMA  STRIDES SHASUN LTD  DISHMAN PHARMA  ALEMBIC LTD  

Compare AMAR REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Flat in Final Hour Sell Off; HDFC Twins Surge(Closing)

Indian share markets witnessed selling pressure in the final hour of trade but still closed at a record high for a third straight session.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The Real Returns from Real Estate Have Been Very Low(Vivek Kaul's Diary)

Jul 17, 2017

Real estate prices across India have barely gone anywhere over the last four years. Prices have fallen in many cities over the last one-year, new data from the National Housing Bank suggests.

Trade the Markets like Roger Federer Plays Tennis(Daily Profit Hunter)

Jul 19, 2017

Trading is one of the most competitive fields in the world today. To win, you must adopt the mindset of a Grand Slam champion.

Sold Your Immoveable Property? Here Are The Tax Implications...(Outside View)

Jul 19, 2017

When you're selling an immoveable property, it becomes imperative to recognise the intricate tax implications.

Why Keeping Unrealistic Expectations From Investments Is Stupid!(Outside View)

Jul 18, 2017

When investing, keeping realistic returns is necessary and it is not the only thing you should look at.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AMAR REMEDIES

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS